CTRI/2017/03/008078
Recruiting
Phase 2
A double-blind, randomized, placebo-controlled efficacy trial of individualized homeopathic treatment of geriatric depression
MBHM College Hospital MHM College Hospital The CHM College Hospital0 sites0 target enrollmentTBD
Overview
- Phase
- Phase 2
- Intervention
- Not specified
- Conditions
- Health Condition 1: null- DepressionHealth Condition 2: F339- Major depressive disorder, recurrent, unspecified
- Sponsor
- MBHM College Hospital MHM College Hospital The CHM College Hospital
- Status
- Recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Aged 60\-80 years, both sexes, and suffering from depression \[Geriatric Depression Score: \>\= 5]
Exclusion Criteria
- •Patients who are too sick for consultation, unwilling to take part, unable to read, and not giving consent to join the study, diagnosed cases of unstable mental or psychiatric illness or other uncontrolled or life\-threatening illness affecting QoL, currently receiving standard psychiatric therapy (conventional medication), chronic alcoholism, drug abuse and/or dependence, self\-reported immune\-compromised state, and undergoing homeopathic treatment for any chronic disease within last 6 months.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Phase 2
Homeopathic treatment of bedwetting in childreHealth Condition 1: N394- Other specified urinary incontinenceCTRI/2022/04/042009D N De Homoeopathic Medical College and Hospital140
Active, not recruiting
Not Applicable
A double-blind, placebo-controlled, randomized efficacy and safety study of levetiracetam extended release formulation (LEV XR), administered as 2 x 500 mg LEV XR tablets once daily as add-on therapy in subjects from 12 to 70 years with refractory epilepsy suffering from partial onset seizuresEUCTR2006-000987-10-FICB S.A.130
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic Idiopathic UrticariaEUCTR2005-002749-38-BEBarrier Therapeutics nv48
Completed
Phase 2
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaChronic urticaria10002426NL-OMON30213Barrier Therapeutics16
Active, not recruiting
Not Applicable
A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria - oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticariaEUCTR2005-002749-38-CZBarrier Therapeutics nv48